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circumference of the vessel). The vascular PTV (PTVv) was 
considered as the CTVv plus an anisotropic margin (5 mm CC, 
3 mm in other directions). The tumor PTV (PTVt) was defined 
as the GTV plus an anisotropic margin (5 mm CC, 3 mm in 
other directions) including the PTVv and excluding the PTVd. 
The following doses were prescribed [in 5 daily fractions (fr)] 
to the PTVs: 30 Gy (6 Gy/fr) to the PTVd, 45 Gy (9 Gy/fr) to 
the PTVv, and 37.5 Gy (7.5 Gy/fr) to the PTVt, respectively. 
Constraints were based on AAPM TG101 recommendations: 
Dmax of PRVduodenum < 32.0 Gy, Dmax of PRVspinal cord < 
30.0 Gy, Dmax of PRVstomach < 32.0%, D700cc liver < 21.0 
Gy, D200 cc kidneys < 17.5 Gy. All plans were generated with 
Masterplan Oncentra TPS and the treatment was delivered 
with a step and shot IMRT technique. The primary end point 
was the rate of patients in whom the constraint Dmean > 90% 
was achieved for the 3 different PTVs. Secondary end points 
were the percentage of patients in whom a PTVv near 
minimum dose (D98%) > 90%, a PTVv D95% > 95%, and a 
median dose (D50%) > 95% were achieved. 
 
Results: PTVv Dmean > 90%, PTVv D2% < 115% and OARs Dmax 
constraints were achieved in all patients. Both PTVv D98% > 
90% and PTVv D95% > 95% were achieved in 6 patients (40%). 
 
Conclusion: Although the objective of PTVv D95% > 95% was 
achieved only in 40% of patients, the study showed that in 
100% of patients it was possible to administer a strongly 
differentiated mean and median dose, and in particular a low 
dose to the overlap region between the target and 
duodenum, a high dose to the site of vascular infiltration, 
and an intermediate dose to the remaining target volume. 
Prospective trials based on clinical application of this 
strategy seems to be justified at least in selected patients. 
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Purpose or Objective: Whole breast irradiation is part of 
breast conservative management for early breast cancer. In 
addition to that boost dose to tumor bed improves local 
recurrence rates and is currently the standard of care. Our 
aim of the current study was to evaluate intensity modulated 
radiation therapy (IMRT) for whole breast versus its 
dosimetric properties of volumetric modulated arc therapy 
(VMAT). 
 
Material and Methods: Eighteen consecutive women with left 
sided breast cancer were taken for this retrospective study. 
IMRT treatment plans were created for patients who already 
received treatment with VMAT. The plans were created in 
Monaco planning system using Monte Carlo (MC) algorithm. 
The Elekta Infinity linear accelerator with Agility MLC is used 
for VMAT delivery. Our clinic uses simultaneous integrated 
boost (SIB) technique to treat whole breast patients. The 
dose prescribed was 60Gy/25# to tumor bed and 45Gy/25# 
for whole breast. The plans were evaluated based on 
QUANTTEC dose-volume protocol. Data were statistically 
analyzed using Wilcoxon Signed Rank test. 
 
Results: VMAT technique statistically significant in target 
coverage and dose conformity than IMRT. In addition to that 
lesser ipsilateral & contra lateral lung dose and reduced 
contra lateral breast dose with VMAT. Critical structures like 
Left descending artery(LAD), Spinal Cord and heart also 
received lower doses with VMAT than IMRT . All the 
dosimetric parameters and its statistical values were 
provided in table1.Statistics shows VMAT more significant for 
LAD, Ipsilateral lung dose and Conformity Index. 
 
 
 
Conclusion: From this study , we infer that, our switch over 
from IMRT to VMAT treatment technique provided better 
dosimetric effect for left sided breast cancer patients. Also 
VMAT provided significant improvement target coverage and 
conformity. It reduced the dose to normal tissues further to 
IMRT. 
 
EP-1651  
Reducing the probability of radiation-induced hepatic 
toxicity by changing the treatment modality 
S.H. Son
1Incheon St. Mary's Hospital, Radiation Oncology, Incheon, 
Korea Republic of 
1 
 
Purpose or Objective: To estimate and compare the risk of 
radiation-induced hepatic toxicity (RIHT) in helical 
tomotherapy and fixed-beam intensity-modulated 
radiotherapy (IMRT) for the treatment of hepatocellular 
carcinoma (HCC). 
 
Material and Methods: Twenty patients with unresectable 
HCC treated with tomotherapy were selected. We performed 
tomotherapy re-planning to reduce the non-target normal 
liver volume receiving a dose of more than 15 Gy (NTNL-
V15Gy), and we created a fixed-beam IMRT plan (FB-P). We 
compared the dosimetric results as well as the estimated 
probability of RIHT among the tomotherapy initial plan (T-IP), 
the tomotherapy re-plan (T-RP), and the FB-P. 
 
Results: Comparing the T-RP and FB-P, the homogeneity 
index was 0.11 better with the T-RP. However, the mean 
NTNL-V15Gy was 6.3% lower with the FB-P. These differences 
result in a decline in the probability of RIHT from 0.216 in 
the T-RP to 0.115 in the FB-P. In patients whose NTNL-V15Gy 
was higher than 43.2% with the T-RP, the probability of RIHT 
markedly reduced from 0.533 to 0.274. 
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Conclusion: By changing the treatment modality from 
tomotherapy to fixed-beam IMRT, we could reduce the liver 
dose and the probability of RIHT without scarifying the target 
coverage, especially in patients whose liver dose is high. 
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Purpose or Objective: Gliomas are the most common brain 
tumor in adult patients and radiotherapy plays an important 
role in the treatment. Nonetheless, the clinical outcome for 
these patients remains poor, due to early local failure, 
suggesting the need for higher tumor doses. This study 
investigates the feasibility of dose escalating an amino acid 
18F-fluoro-ethyl-tyrosine (FET) PET defined biological target 
volume (BTV) in glioma patients by IMRT, VMAT and IMPT. 
 
Material and Methods: Seven patients were eligible for this 
study. All patients received a pre therapeutic FET-PET/CT 
and MRI. To compare, standard IMRT treatment plans giving 
60 Gy in 30 fractions to the BTV and 46 Gy to the CTV(46 Gy) 
were calculated. CTV(46 Gy) was defined as tumor and/or 
tumor cavity plus 2 cm. The BTV was generated from the FET 
PET image and covered a tumor-to-brain cut-off ratio of FET 
uptake ≥ 1.6 (pre-surgery) ≥ 2.1 (post-surgery). Both BTV and 
CTV(46 Gy) were checked visually and adapted to anatomic 
barriers. Planning target volumes, PTV boost and PTV(46 Gy) 
were generated by adding 3 mm uniformly to the BTV and 
CTV(46 Gy), respectively. The standard IMRT plans were used 
to define the base level of dose to the organs at risk (OAR) 
and PTV(46 Gy) homogeneity. To evaluate the dose to the 
OAR the mean OAR was used and the PTV(46 Gy) 
homogeneity was defined as the volume of PTV(46 Gy) 
subtracted PTV boost which received 107% of the prescribed 
46 Gy. Then, IMRT, VMAT and IMPT dose escalating treatment 
plans were calculated in order to get the highest achievable 
mean PTV boost dose, without increasing the mean dose to 
critical OAR and without decreasing the PTV(46 Gy) 
homogeneity. For all plans the dose boost was given as the 
integrated boost over 30 fractions. All treatment plans were 
carried out using the Eclipse treatment planning system 
(Varian Medical systems, Palo Alto, CA, USA). 
 
Results: A standard IMRT plans were calculated for all 
patients and the base level for PTV(46 Gy) homogeneity was 
found to range between 65 % to 86 %, with a median value of 
77%. Dose escalating, while maintaining this homogeneity, 
was found feasible using all three techniques. The obtainable 
mean and maximum doses were respective 77.1 Gy and 82.5 
Gy for IMRT, 79.2 Gy and 87.4 Gy for VMAT and 85.1 Gy and 
89.9 Gy for IMPT. On top of the significant increase in mean 
and maximum PTV boost dose obtained for IMPT, the PTV(46 
Gy) homogeneity can be decreased to a median value of 
30.4%.  
 
Conclusion: Dose escalating a FET PET based target volume 
to above 77 Gy in 30 fractions by IMRT, VMAT, and IMPT 
without increasing both the PTV(46 Gy) homogeneity and the 
mean dose to the OAR was found feasible. For IMPT the 
PTV(46 Gy) homogeneity could be substantially reduced, 
implicating the reduction of the risk of brain necrosis despite 
the increased mean and maximum PTV boost doses. 
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Purpose or Objective: Brain metastases are a very frequent 
situation in advanced cancer and whole brain radiotherapy 
(WBRT) has long been considered the standard of care. 
Stereotactic radiosurgery has been shown to be effective in 
terms of survival and quality of life for patients with a better 
prognostic profile and a limited number (1 to 3) of brain 
metastases. More recent experiences have shown the efficacy 
of stereotactic radiation for multiple brain metastases as 
well. This may allow deferment of WBRT, in order to limit 
the risk of acute toxicity and late neurocognitive decline. 
The goal of the present study was to test from a dosimetric 
point of view a new planning software, BrainMetastases ® 
(BM) (BrainLab®, Feldkirchen - Germany), and to compare it 
with RapidArc (RA) ® plan TPS. (Varian®, Palo Alto CA, USA) 
 
Material and Methods: We retrospectively re-planned 12 
patients treated for 2 or more brain metastases in our 
institute. Median age was 53 (range 41-63). The most 
frequent number of metastases per patient was 3 (range 2-
10). The new BM software creates a dynamic arc plan 
following a simple PTV and geometrical constrains and 
calculates it with the pencil beam algorithm. For all the 
patients we studied, a plan using both BM and RA with 
different prescriptions (1x20Gy, 5x7Gy, RTOG protocol) and 
for RA plans we also considered two different plans with 6MV 
and the 10FFF beams. Finally the dosimetric parameters were 
extracted from the DVHs. 
 
Results: As PTV constraint we decided that the prescribed 
dose should cover the 90% of the PTV volume. With this 
normalization we obtained a better conformity index for RA 
plan and a smaller Healthy Brain mean dose with the BM 
plan. In particular for the patients with 3 metastases with 
6MV beam and the 5x7Gy prescription the CI99% was 1.0 1± 
0.18 and 1.56 ± 1.30 and Healthy Brain mean dose 3.0 ± 1.2 
Gy and 2.4 ± 1.1 Gy and V20Gy 13.0±6.4 cm3 and 9.6±6.5 
cm3 respectively for RA and BM technique. Also the time for 
optimization and calculation are 14.4±5.53 minutes and 
3.63±1.48 minutes. The algorithm implemented in BM is the 
pencil beam and evaluated the dose every 5° and in Eclipse is 
Acuros XB and the calculation is performed every 2°. A more 
detailed analysis concerning the OAR sparing will be 
reported. 
 
Conclusion: Plan optimisation using BM software provides a 
satisfactory dose distribution with a good conformity index 
and organs at risk sparing; the results are comparable with a 
VMAT plan. Reduction of time for optimisation and 
calculation seems to favour the BM software, with a similar 
OAR safety. Nevertheless these assumptions need to be 
balanced with the clinical experience which is currently 
ongoing in different institutes. 
 
 
 
 
